Eli Lilly warns EU will miss out on key drugs under new patent rules
The chief executive of one of the world’s biggest pharma groups has warned Europe may miss out on new drugs for conditions such as heart disease and cancer if it pushes ahead with “troubling” new legislation.
David Ricks, Eli Lilly’s chief executive, said under a draft plan to cut market exclusivity protection from 10 to eight years, it might not be worth the industry pursuing treatments for chronic diseases or cancer trials.
This story originally appeared on: Financial Times - Author:Jamie Smyth
